H1 2026 revenue is expected to rise 4% year-over-year to £115.2 million, with EBITDA for the full year on track to meet market expectations. Strategic expansion of direct sales and integration of recent acquisitions support long-term growth and margin improvement.Original document: Advanced Medical…
H1 2026 revenue is expected to rise 4% year-over-year to £115.2 million, with EBITDA for the full year on track to meet market expectations. Strategic expansion of direct sales and integration of recent acquisitions support long-term growth and margin improvement.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.